| olanzapine / Generic mfg. |
| Completed | 2a | 106 | US | AZD2624, Olanzapine, Zyprexa, Placebo | AstraZeneca | Schizophrenia | 03/09 | 03/09 | | |
NCT00827918: A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) |
|
|
| Completed | 2a | 216 | RoW | MK-8998, Comparator: Olanzapine, Comparator: Placebo | Merck Sharp & Dohme LLC | Schizophrenia | 04/10 | 04/10 | | |
NCT03557931: A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication |
|
|
| Completed | 2a | 233 | US | ASP4345, placebo, risperidone, Risperdal, quetiapine, Seroquel, olanzapine, Zyprexa, ziprasidone, Geodon, aripiprazole, Abilify, brexpiprazole, Rexulti, paliperidone, Invega, lurasidone, Latuda | Astellas Pharma Global Development, Inc. | Schizophrenia | 10/19 | 10/19 | | |
CALM 201, NCT05163717: INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD |
|
|
| Terminated | 2a | 8 | US | INP105, POD-OLZ, Placebo, POD-placebo, POD-PBO | Impel Pharmaceuticals | Agitation in Adolescents and Young Adults With ASD | 03/23 | 04/23 | | |
ACTRN12622001532796: A multicentre, cluster randomised, double cross over pragmatic clinical trial comparing the safety and efficacy of enteral olanzapine with quetiapine in critically ill patients with hyperactive delirium |
|
|
| Not yet recruiting | 2 | 1200 | | | Royal Melbourne Hospital, The Australian and New Zealand Intensive Care Foundation | critical illness, hyperactive delirium | | | | |
| Recruiting | 2 | 24 | | | The University of Technology Sydney , The University of Technology Sydney | Nausea
, Advanced Cancer | | | | |
ACTRN12619000284167: Use of the antipsychotic olanzapine to treat agitation in traumatic brain injury |
|
|
| Recruiting | 2 | 58 | | | Monash University, Monash Epworth Rehabilitation Research Centre | Traumatic brain injury, Post-traumatic amnesia, Agitation | | | | |
PATROL-II, UMIN000038644: A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer |
|
|
| Recruiting | 2 | 89 | Japan | Aloxi (palonosetron oral) - Helsinn, Otsuka, Roche, Eisai, Immedica, aprepitant oral - Generic mfg., olanzapine - Generic mfg. | Hoshi University; Division of Applied Pharmaceutical, University of Shizuoka, School of Pharmaceutical Sciences | Breast cancer;Oncology | | | | |
| Completed | 2 | 78 | US | olanzapine (Zyprexa), Antipsychotic Drug, Placebo, Placebo controlled | FDA Office of Orphan Products Development, National Institute of Mental Health (NIMH) | Autistic Disorder | | 09/05 | | |
NCT00260962: Olanzapine in the Treatment of Patients With Anorexia Nervosa |
|
|
| Completed | 2 | 34 | Canada | Olanzapine, Zyprexa, Day Hospital | Ottawa Hospital Research Institute, Eli Lilly and Company | Anorexia Nervosa | 07/06 | 09/06 | | |
NCT00149292: Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo |
|
|
| Completed | 2 | 195 | RoW | LY2140023, olanzapine, placebo | Denovo Biopharma LLC | Schizophrenia | 07/06 | 07/06 | | |
NCT00073164: Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia |
|
|
| Completed | 2 | 400 | US | Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone | Abbott | Schizophrenia | | | | |
NCT00265551: Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia |
|
|
| Completed | 2 | 300 | US | SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo | Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia | | 01/07 | | |
NCT00455442: A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain |
|
|
| Completed | 2 | 57 | RoW | Mifepristone | Corcept Therapeutics, Eli Lilly and Company | Weight-Gain Prevention | | 07/07 | | |
| Completed | 2 | 338 | US, Europe, RoW | SB-773812, Olanzapine | GlaxoSmithKline | Schizophrenia | | 08/07 | | |
NCT00483964: A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia |
|
|
| Completed | 2 | 200 | RoW | Bacopa monnieri, Nardostachys jatamansi, Olanzapine | Q.Mundewadi Ayurvedic Research & Charitable Trust, Stanley Medical Research Institute | Schizophrenia | | 09/07 | | |
2006-006184-23: A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of Schizophrenia. A phase IIb, international, multicentre, 8-week study |
|
|
| Ongoing | 2 | 480 | Europe | S33138, ZYPREXA, S33138, Film-coated tablet, ZYPREXA | Institut de Recherches Internationales Servier | Schizophrenia | | | | |
NCT00678457: Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial |
|
|
| Completed | 2 | 40 | US | Ondansetron, Zofran, Olanzapine, Zyprexa, Placebo | University of Virginia | Alcohol Dependence | 05/08 | 05/08 | | |
NCT00428168: Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment |
|
|
| Terminated | 2 | 36 | Canada, RoW | Betahistine | OBEcure Ltd. | Weight Gain | 08/08 | 12/08 | | |
| Completed | 2 | 654 | Europe, RoW | LY2140023, Olanzapine, Placebo | Eli Lilly and Company | Schizophrenia | 10/08 | 10/08 | | |
NCT00734435: Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects |
|
|
| Terminated | 2 | 26 | US | zonisamide SR plus olanzapine, Zyprexa, Placebo plus olanzapine | Orexigen Therapeutics, Inc | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder | 12/08 | 12/08 | | |
CONNECT, NCT00439634: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia |
|
|
| Terminated | 2 | 873 | US, Canada | AVE1625, Drinabant, placebo | Sanofi | Schizophrenia | 09/09 | 09/09 | | |
| Completed | 2 | 93 | Europe, RoW | Zicronapine, Lu 31-130, Olanzapine, Zyprexa | H. Lundbeck A/S | Schizophrenia | 10/09 | 11/09 | | |
| Completed | 2 | 498 | Europe, RoW | JNJ-37822681, Olanzapine, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 02/10 | 02/10 | | |
|
|
| Completed | 2 | 261 | Europe, US, RoW | LY2140023, pomaglumetad methionil, aripiprazole, Abilify, olanzapine, Zyprexa, risperidone, Risperdal | Denovo Biopharma LLC | Schizophrenia | 05/10 | 12/10 | | |
|
|
NCT00692185: Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa |
|
|
| Completed | 2 | 23 | US | Olanzapine, zyprexa, Placebo | New York State Psychiatric Institute, National Institute of Mental Health (NIMH) | Eating Disorders | 09/10 | 09/10 | | |
STAR-1, NCT00509067: Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia |
|
|
| Completed | 2 | 43 | US | Galantamine, Razadyne, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole | Georgetown University, National Institute of Mental Health (NIMH), Washington D.C. Veterans Affairs Medical Center | Schizophrenia | 03/11 | 03/11 | | |
| Completed | 2 | 167 | Europe, US, RoW | LY2140023, pomaglumetad methionil, Placebo, Standard of Care | Denovo Biopharma LLC | Schizophrenia | 06/12 | 06/12 | | |
|
| Withdrawn | 2 | 0 | RoW | SCH 900435 (Org 25935), Placebo, Olanzapine, Zyprexa® | Merck Sharp & Dohme LLC | Schizophrenia | 07/12 | 07/12 | | |
2007-003775-39: Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis |
|
|
| Terminated | 2 | 34 | Europe | Tablet, Zyprexa | Charité – Universitätsmedizin Berlin | patients with amyotrophic lateral sclerosis | | | | |
| Completed | 2 | 301 | US, Europe, RoW | bitopertin [RO4917838], olanzapine, placebo | Hoffmann-La Roche | Schizophrenia | 09/12 | 09/12 | | |
| Terminated | 2 | 2 | Europe | GWP42003 : GWP42004 (40:1), Placebo | Jazz Pharmaceuticals | Schizophrenia | 10/12 | 10/12 | | |
NCT01323205 / 2010-023369-23: Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia |
|
|
| Completed | 2 | 100 | Europe | JNJ-40411813, Placebo, Antipsychotic medication | Janssen Research & Development, LLC | Schizophrenia | 11/12 | 12/12 | | |
NCT01272765: Anti-psychotic Medication (Stable Dose) Weight Loss Study |
|
|
| Withdrawn | 2 | 0 | US | Placebo, sugar pill, IHBG-10, IHBG10 | Avera McKennan Hospital & University Health Center | Obesity | 01/13 | 01/13 | | |
| Completed | 2 | 18 | RoW | D-serine, DSR, Olanzapine, Zyprexa | Herzog Hospital, Israel Science Foundation | Schizophrenia | 02/13 | 02/13 | | |
NCT01593774: Melatonin for Prevention of Metabolic Side Effects of Olanzapine |
|
|
| Completed | 2 | 36 | RoW | Melatonin, Placebo | Guilan University of Medical Sciences | Schizophrenia | 03/13 | 03/13 | | |
| Terminated | 2 | 23 | Europe | olanzapine, Zyprexa, metoclopramide, Paspertin | Karin Jordan | Emesis | 10/13 | 10/14 | | |
NCT01272752: Anti-psychotic Medication (New Use) Weight Loss Study |
|
|
| Withdrawn | 2 | 0 | US | IHBG-10, IHBG10, Placebo, sugar pill | Avera McKennan Hospital & University Health Center | Obesity | 12/13 | 12/13 | | |
NCT02097823: Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy |
|
|
| Completed | 2 | 15 | US | Olanzapine, zyprexa, Aprepitant, emend | Indiana University | Chemotherapy Induced Nausea and Vomiting | 02/15 | 03/15 | | |
NCT02290470: Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel |
|
|
| Unknown status | 2 | 81 | Europe | Olanzapine, Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Nausea, Vomiting | 11/15 | 11/15 | | |
KSWOG 15-01, NCT02400866: A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy |
|
|
| Unknown status | 2 | 58 | NA | Olanzapine | Korean South West Oncology Group | Cancer | 11/15 | 04/17 | | |
2004-001041-15: MULTICENTRE, DOUBLE-BLIND, RISING DOSE PARALLEL GROUP STUDY OF THE EFFICACY AND TOLERABILITY OF OCAPERIDONE VERSUS OLANZAPINE IN SCHIZOPHRENIC PATIENTS |
|
|
| Completed | 2 | 10 | Europe | Ocaperidone, Zyprexa, Zyprexa, Zyprexa | Neuro3d | The populations of the study will be:-schizophrenic patients according to DSM IV-TR diagnosis-have to present the first symptoms of the schizophrenia for at least one year-have to present an exacerbation of the disease but without risk of suicide-must not have clinically significant disease or biological/ECG abnormality which might create a risk for the patient, obscure the effects of study treatment or interfere with drug absorption, metabolism or excretion | | | | |
2006-004783-31: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine |
|
|
| Ongoing | 2 | 50 | Europe | AZD3480, | AstraZeneca AB | Schizophrenia | | | | |
NCT02129478: Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study |
|
|
| Completed | 2 | 15 | Canada | Olanzapine, Zyprexa | The Hospital for Sick Children, Pediatric Oncology Group of Ontario | Chemotherapy-induced Nausea and Vomiting | 01/16 | 01/16 | | |
NCT02462473: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry |
|
|
| Terminated | 2 | 9 | US | Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone | Janssen Research & Development, LLC | Schizophrenia, Schizoaffective Disorder | 01/16 | 01/16 | | |
ChiCTR1800017724: Olanzapine combined with dexamethasone, and palonosetron for preventing nausea and vomiting induced by highly emetogenic chemotherapy : a phase II trial |
|
|
| Not yet recruiting | 2 | 40 | | olanzapine combined anti-nausea scheme | Chinese PLA General hospital; Chinese PLA General hospital, scientific research task of Beijing | nausea and vomiting induced by highly emetogenic chemotherapy | | | | |
OMCINV, ChiCTR1800015876: A randomized controlled clinical trial of Olanzapine or Metoclopramide combined with 5-HT3 receptor antagonist and dexamethasone for the prevention and treatment of nausea and vomiting associated with chemotherapy including Cisplatin |
|
|
| Recruiting | 2 | 150 | | olanzapine ;metoclopramide ;olanzapine combine with metoclopramide | Hunan Provincial People's Hospital; Hunan Provincial People's Hospital, The Olanzapine Tablets needed for this clinical trial is provided by the Jiangsu haosen pharmaceutical Limited by Share Ltd. | malignant tumor | | | | |
OlaCINV, NCT03478605: Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis |
|
|
| Unknown status | 2 | 130 | RoW | Olanzapine, Zyprexa, Aprepitant Pill, Emend, Ondansetron, Dexamethasone | Blokhin's Russian Cancer Research Center, RUSSCO/RakFond | Emesis, Vomiting, Nausea Post Chemotherapy, Nausea, Chemotherapy-induced Nausea and Vomiting | 05/19 | 06/19 | | |
| Completed | 2 | 180 | US | Olanzapine, Zyprexa, 132539-06-1, Zyprexa Zydis, Olansek, Symbyax2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, Placebo | Jaime B Hyman | Postoperative Nausea and Vomiting | 09/19 | 09/19 | | |
NCT03319953: A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia |
|
|
| Completed | 2 | 23 | Europe | TAK-041, Placebo, Second Generation Antipsychotics (SGA) | Neurocrine Biosciences, Takeda | Stable Schizophrenia | 09/19 | 11/19 | | |
NCT03679182: Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care |
|
|
| Unknown status | 2 | 15 | RoW | Olanzapine, olanzapine 5 mg Tab | Khon Kaen University | Nausea, Vomiting, End Stage Cancer | 09/20 | 09/21 | | |
NCT03960151: Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy |
|
|
| Withdrawn | 2 | 0 | NA | Rolapitant, Varubi, Palonosetron, Aloxi, Olanzapine, Zyprexa, Dexamethasone, steroid | Costantine Albany, Tesaro, Inc. | Germ Cell Tumor | 05/21 | 03/22 | | |
NCT03575637: Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer |
|
|
| Unknown status | 2 | 180 | RoW | Olanzapine | Peking University | Gastric Cancer | 05/21 | 06/21 | | |
OLNEPA, NCT04669132: Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer |
|
|
| Completed | 2 | 50 | RoW | Olanzapine, Netupitant, Palonesetron | Instituto Brasileiro de Controle do Cancer | Nausea Post Chemotherapy | 12/21 | 01/22 | | |
NCT02088060 / 2012-004335-23: A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients |
|
|
| Active, not recruiting | 2 | 150 | Europe | Cannabidiol, Olanzapine, Olanzapine 1A pharma, Placebo Cannabidiol, Placebo Olanzapine | Central Institute of Mental Health, Mannheim, Martin-Luther-Universität Halle-Wittenberg, Heidelberg University, Technical University of Munich, Ludwig-Maximilians - University of Munich, Glostrup University Hospital, Copenhagen | Schizophrenia | 12/24 | 06/25 | | |
NCT05202275: The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs |
|
|
| Recruiting | 2 | 43 | RoW | Olanzapine, Palonosetron, Aprepitant | Chinese Academy of Medical Sciences | Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect | 12/22 | 09/23 | | |
NCT05170919: Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer |
|
|
| Enrolling by invitation | 2 | 170 | US | Mirtazapine, Olanzapine | Englewood Hospital and Medical Center | Anorexia Nervosa With Significantly Low Body Weight | 12/22 | 12/23 | | |
| Withdrawn | 2 | 0 | US | Olanzapine | University of Pennsylvania | Opioid Use Disorder | 01/23 | 01/23 | | |
CLOZ-AID, NCT04529226: Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis |
|
|
| Active, not recruiting | 2 | 75 | Europe | Clozapine, Nemex, Leponex, haloperidol, pimozide, olanzapine, risperidone, amisulpride | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Psychosis, Intellectual Disability | 01/25 | 12/25 | | |
NCT06065722: Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy |
|
|
| Recruiting | 2 | 100 | US | Akynzeo, Olanzapine | Simon Williamson Clinic, Helsinn Healthcare SA | Chemotherapy Induced Nausea and Vomiting | 12/23 | 12/23 | | |
| Recruiting | 2 | 80 | RoW | Haloperidol Solution, Olanzapine Tablets | HCA Hospice Care | Delirium, Terminal Illness | 05/24 | 05/24 | | |
NCT04518319: Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome |
|
|
| Suspended | 2 | 120 | RoW | Omega-3 polyunsaturated fatty acids, Xbox aerobic exercise, transcranial direct current stimulation,tDCS, Olanzapine | Shanghai Mental Health Center | Schizophrenia | 11/24 | 11/24 | | |
NCT05705492: Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 66 | US | Olanzapine, LY 170053, Zyprexa, Zyprexa Zydis, Placebo Administration, Questionnaire Administration | OHSU Knight Cancer Institute, Oregon Health and Science University, National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm | 06/25 | 12/25 | | |
| Recruiting | 2 | 180 | Europe | Cannabidiol as add-on, Placebo as add-on | Central Institute of Mental Health, Mannheim | Schizophrenia | 12/24 | 12/25 | | |
NCT03118986: RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy |
|
|
| Recruiting | 2 | 200 | Canada, US, RoW | Olanzapine, Placebo Oral Tablet | The Hospital for Sick Children, University of California, San Francisco, Children's Mercy Hospital Kansas City, St. Justine's Hospital, Columbia University, Medical University of South Carolina, CancerCare Manitoba, University of North Carolina, Chapel Hill, Nationwide Children's Hospital | Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology | 03/25 | 04/25 | | |
NCT05676294: The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery |
|
|
| Recruiting | 2 | 455 | US | Olanzapine, Zyprexa, Placebo | Yale University | Postoperative Nausea and Vomiting | 01/26 | 01/26 | | |
NCT01282632: Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression |
|
|
| Completed | 1/2 | 42 | Canada | Risperidone, Olanzapine | Sunnybrook Health Sciences Centre | Subjects Had Unipolar, Non-psychotic Major Depression | 03/04 | 03/04 | | |
NCT00089869: A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia |
|
|
| Completed | 1/2 | | US | olanzapine, atomoxetine, placebo | Eli Lilly and Company | Schizophrenia | | | | |
| Completed | 1/2 | 30 | Europe | Olanzapine, Zyprexa, Zydis, Relprevv | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Schizophrenia | 03/10 | 03/10 | | |
| Withdrawn | 1/2 | 0 | US | Risperidone plus Placebo, Risperdal, Risperidone plus DMXB-A | VA Office of Research and Development, University of Colorado, Denver | Schizophrenia | 08/16 | 08/16 | | |
NCT02650102: The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment |
|
|
| Unknown status | 1/2 | 200 | RoW | Risperidone, Risperdal, Olanzapine, Zyprexa, Quetiapine, Seroquel, Aripiprazole, Abilifya, Ziprasidone, Geodon | Shanxi Medical University | Schizophrenia | 12/16 | 12/16 | | |
NCT04718727: Olanzapine for the Prevention of Postoperative Nausea and Vomiting |
|
|
| Completed | 1/2 | 132 | RoW | Placebo, 5 mg Olanzapine Tablets, zyprexa, 10 mg Olanzapine Tablets | Amani Hassan Abdel-Wahab | Postoperative Nausea | 02/23 | 02/23 | | |
STAMD, NCT05814640: Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) |
|
|
| Recruiting | 1/2 | 520 | RoW | Fluoxetine, Sertraline, Vortioxetine, Duloxetine, Aripiprazole, Lithium Carbonate, Olanzapine, GCBT | First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Chongqing Medical University, Children's Hospital of Chongqing Medical University, Southwest Hospital, China, Central South University | Depression, Sequestra | 12/25 | 07/27 | | |
